Immunization with bacterial ghost-based vaccines

Details Immunization with bacterial ghost-based vaccines Immunization with bacterial ghost-based vaccines

2009-05-01

2010-12-28

Minnifield, N. M (Department: 1645)

Chemistry: molecular biology and microbiology

Micro-organism, per se ; compositions thereof; proces of...

C435S259000

Reexamination Certificate

active

07858357

ABSTRACT:
Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain, homolog or functional derivative thereof. The method includes treating the cell-wall material with a solution capable of removing a cell-wall component such as a protein, lipoteichoic acid or carbohydrate from the cell-wall material and contacting the proteinaceous substance with the cell-wall material.

REFERENCES:
patent: 5470573 (1995-11-01), Lubitz et al.
patent: 5616686 (1997-04-01), Fischetti et al.
patent: 5786205 (1998-07-01), Fischetti et al.
patent: 5821088 (1998-10-01), Darzins et al.
patent: 5955258 (1999-09-01), Buist et al.
patent: 6027910 (2000-02-01), Klis et al.
patent: 6114147 (2000-09-01), Frenken et al.
patent: 6177083 (2001-01-01), Lubitz
patent: 6423316 (2002-07-01), Riesbeck et al.
patent: 6827940 (2004-12-01), Riordan et al.
patent: 6896887 (2005-05-01), Leenhouts et al.
patent: 7067639 (2006-06-01), Leenhouts et al.
patent: 7169383 (2007-01-01), Buist et al.
patent: 7312311 (2007-12-01), Buist et al.
patent: 7541039 (2009-06-01), Leenhouts et al.
patent: 2003/0180816 (2003-09-01), Leenhouts et al.
patent: 2006/0115491 (2006-06-01), Leenhouts et al.
patent: 2008/0193427 (2008-08-01), Kaesler et al.
patent: 2008/0263414 (2008-10-01), Saito et al.
patent: 2009/0239264 (2009-09-01), Leenhouts et al.
patent: 3919644 (1990-12-01), None
patent: 198 00 746 (1999-07-01), None
patent: 0 545 352 (1993-06-01), None
patent: 0 712 935 (1996-05-01), None
patent: 02065790 (1990-03-01), None
patent: 10117783 (1998-05-01), None
patent: 2002017357 (2002-01-01), None
patent: WO 91/13155 (1991-09-01), None
patent: WO 92/01791 (1992-02-01), None
patent: WO 94/01567 (1994-01-01), None
patent: WO 94/18330 (1994-08-01), None
patent: WO 95/31561 (1995-11-01), None
patent: WO 96/00579 (1996-01-01), None
patent: WO 96/11263 (1996-04-01), None
patent: WO 96/40943 (1996-12-01), None
patent: WO 97/28263 (1997-08-01), None
patent: WO 98/07874 (1998-02-01), None
patent: WO 98/42850 (1998-10-01), None
patent: WO 99/25836 (1999-05-01), None
patent: WO 00/44878 (2000-08-01), None
patent: WO 00/53163 (2000-09-01), None
patent: WO 01-09350 (2001-02-01), None
patent: WO 01/54672 (2001-08-01), None
patent: WO 01/91791 (2001-12-01), None
patent: WO 02/101026 (2002-12-01), None
Bolotin et al., The Complete Genome Sequence of the Lactic Acid BacteriumLactococcus lactisssp.lactisIL1403, Genome Research, 2001, pp. 731-753, vol. 11.
Brown et al., Comparison of Various Procedures for Removing Proteins and Nucleic Acids from Cell Walls ofBacillus subtilis, 1976, pp. 479-488.
Buist et al., Molecular Cloning and Nucleotide Sequence of the Gene Encoding the Major Peptidoglycan Hydrolase ofLactococcus lactis, a Muramidase Needed for Cell Separation, Journal of Bacteriology, Mar. 1995, pp. 1554-1563, vol. 177, No. 6.
Cibik et al., Identification of Mur, an Atypical Peptidoglycan Hydrolase Derived from Leuconostoc citreum, Applied and Environmental Microbiology, Feb. 2001, pp. 858-864, vol. 67, No. 2.
European Search Report, EP 01 20 2239, dated Jan. 14, 2002.
Fischetti et al., 1996, Gram-positive commensal bacteria for mucosal vaccine delivery. Current Opinions in Biotechnology v7:659-666.
Furst-Ladani et al., Vaccine. 2000, 18:440-448.
Gasson et al., Plasmid Complements ofStreptococcus lactisNCDO 712 and Other LacticStreptococciAfter Protoplast-Induced Curing, Journal of Bacteriology, Apr. 1983, pp. 1-9, vol. 154, No. 1.
Haslberger et al., J. Biotechnology, 2000, 83:57-66.
Hatfaludi et al., J. Agric. Food Chem., 2004, 52:5627-5634.
Hoffelner et al., International J. Medical Microbiology, 2004, pp. 303-311, vol. 294.
Huter et al., J. Controlled Release, 1999, 61:51-63.
Jalava et al., J. Controlled Release, 2002, 85:17-25.
Jalava et al., Abstract, Expert Review of Vaccine, Feb. 2003, pp. 45-51, vol. 2, No. 1.
Kok et al., Nucleotide Sequence of the Cell Wall Proteinase Gene ofStreptococcus cremorisWg2, Applied and Environmental Microbiology, Jan. 1988, p. 231-38, vol. 54, No. 1.
Kuipers et al., Controlled overproduction of proteins by lactic acid bacteria, Trends in Biotechnology, Apr. 1997, pp. 135-140, vol. 15.
Lubitz, Expert Opinion Biol. Ther., 2001, 1/5:765-771.
Marchart et al., Vaccine, 2003, 21:1415-22.
Mayrhofer et al., J. Controlled Release, 2005, pp. 725-735, vol. 102.
Medaglini et al., Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacteriumStreptococcus gordoniiafter oral colonization, Proc. Natl. Acad. Sci., Jul. 1995, pp. 6868-6872, vol. 92.
Morata et al., Study of the Morphology of the Cell Walls of Some Strains of Lactic Acid Bacteria and Related Species, Journal of Food Protection, 1998, pp. 557-562, vol. 61, No. 5.
Moorthy et al., Vaccine, 2007, pp. 3636-3645, vol. 25.
Navarre et al., Proteolytic cleavage and cell wall anchoring at the LPXTG motif of surface proteins in Gram-positive bacteria, Molecular Microbiology, 1994, pp. 115-121, vol. 14, No. 1.
Norton et al., Factors affecting the immunogenicity of tetanus toxin fragment C expressed inLactococcus lactis, FEMS Immunology and Medical Microbiology, 1996, pp. 167-177, vol. 14.
Norton et al., The immune response toLactococcus lactis: Implications for its use as a vaccine delivery vehicle, Federation of European Microbiological Societies, 1994, pp. 249-256, vol. 120.
Paukner et al., J. Controlled Release, 2004, 94:63-74.
Paukner et al., J. Drug Targeting, Apr. 2003, 11/3:151-61.
Poquet et al., HtrA is the unique surface housekeeping protease inLactococcus lactisand is required for natural protein processing, Molecular Microbiology, 2000, p. 1042-51, vol. 35, No. 5.
Pozzi et al., 1992, Delivery and expression of a heterologous antigen on the surface ofStreptococci, Infection and Immunity, v60(5):1902-07.
Ramasamy et al., Antibodies to a merozoite surface protein promote multiple invasion of red blood cells by malaria parasites, Parasite Immunology, 1999, pp. 397-407, vol. 21.
Ramasamy et al., Studies on glycoproteins in the human malaria parasitePlasmodium falciparum. Identification of a myristilated 45kDa merozoite membrane glycoprotein, Immunol. Cell Biol., 1987, pp. 419-424, vol. 65, Pt. 5.
Ramasamy et al., Vaccine, 2006, pp. 3900-3908, vol. 24.
Robinson et al., Oral vaccination of mice against tetanus with recombinantLactococcus lactis, Nature Biotechnology, Jul. 1997, pp. 653-657, vol. 15.
Sauve et al., Concentration of Dilute Protein for Gel Electrophoresis, Analytical Biochemistry, 1995, pp. 382-383, vol. 226.
Stahl et al., Bacterial surface display: trends and progress, Trends in Biotechnology, pp. 185-192, vol. 15, 1997.
Szostak et al., J. Biotechnology, 1996, 44, 161-70.
Tabrizi et al., Current Opinion in Biotechnology, 2004, pp. 530-537, vol. 15.
PCT International Search Report, PCT/NL2002/000383, dated Aug. 4, 2003.

Affiliated with

Also associated with

Rating

Immunization with bacterial ghost-based vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunization with bacterial ghost-based vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunization with bacterial ghost-based vaccines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4158414